Key terms
About HOTH
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest HOTH news
Apr 11
4:19pm ET
Hoth Therapeutics files to sell 5.03M shares of common stock for holders
Apr 05
6:26am ET
Promising Preclinical Alzheimer’s Candidate and Diverse Pipeline Bolster Hoth Therapeutics’ Buy Rating
Apr 02
9:08am ET
Hoth Therapeutics price target raised to $7 from $6.50 at EF Hutton
Mar 22
11:33am ET
Biotech Alert: Searches spiking for these stocks today
Mar 21
11:18am ET
Biotech Alert: Searches spiking for these stocks today
Mar 19
8:27am ET
Hoth Therapeutics announces positive preclinical research in Alzheimer’s
Feb 29
8:39am ET
Hoth Therapeutics retains Venable to expand patent portfolio
Feb 26
8:22am ET
Hoth Therapeutics engages Altasciences to perform key study for HT-KIT
Feb 05
6:15am ET
Buy Rating for Hoth Therapeutics: Promising HT-001 Prospects and Diverse Clinical Pipeline
Feb 05
6:11am ET
Hoth Therapeutics initiated with a Buy at H.C. Wainwright
Jan 18
8:23am ET
Hoth Therapeutics receives FDA clearance for amendments in HT-001 clinical trial
No recent press releases are available for HOTH
HOTH Financials
Key terms
Ad Feedback
HOTH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
HOTH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
